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Abstract
The resistance-nodulation-division (RND) efflux systems are ubiquitous transporters that function in antimicrobial resistance.
Recent studies showed that RND systems were required for virulence factor production in Vibrio cholerae. The V. cholerae
genome encodes six RND efflux systems. Three of the RND systems (VexB, VexD, and VexK) were previously shown to be
redundant for in vitro resistance to bile acids and detergents. A mutant lacking the VexB, VexD, and VexK RND pumps
produced wild-type levels of cholera toxin (CT) and the toxin co-regulated pilus (TCP) and was moderately attenuated for
intestinal colonization. In contrast, a RND negative mutant produced significantly reduced amounts of CT and TCP and
displayed a severe colonization defect. This suggested that one or more of the three uncharacterized RND efflux systems
(i.e. VexF, VexH, and VexM) were required for pathogenesis. In this study, a genetic approach was used to generate a panel
of V. cholerae RND efflux pump mutants in order to determine the function of VexH in antimicrobial resistance, virulence
factor production, and intestinal colonization. VexH contributed to in vitro antimicrobial resistance and exhibited a broad
substrate specificity that was redundant with the VexB, VexD, and VexK RND efflux pumps. These four efflux pumps were
responsible for in vitro antimicrobial resistance and were required for virulence factor production and intestinal colonization.
Mutation of the VexF and/or VexM efflux pumps did not affect in vitro antimicrobial resistance, but did negatively affect CT
and TCP production. Collectively, our results demonstrate that the V. cholerae RND efflux pumps have redundant functions
in antimicrobial resistance and virulence factor production. This suggests that the RND efflux systems contribute to V.
cholerae pathogenesis by providing the bacterium with protection against antimicrobial compounds that are present in the
host and by contributing to the regulated expression of virulence factors.
Citation: Taylor DL, Bina XR, Bina JE (2012) Vibrio cholerae vexH Encodes a Multiple Drug Efflux Pump That Contributes to the Production of Cholera Toxin and the
Toxin Co-Regulated Pilus. PLoS ONE 7(5): e38208. doi:10.1371/journal.pone.0038208
Editor: Jamunarani Vadivelu, University of Malaya, Malaysia
Received March 5, 2012; Accepted May 2, 2012; Published May 30, 2012
Copyright:  2012 Taylor et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The project described was supported by award numbers R01AI091845 and R21AI092007 from the National Institute of Allergy and Infectious Diseases.
The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: JBina@pitt.edu
Introduction
Vibrio cholerae is a Gram negative, motile, facultative anaerobic
bacterium, and the causative agent of cholera, a severe diarrhoeal
disease, which untreated can rapidly lead to dehydration,
hypotensive shock, and death. V. cholerae is a common inhabitant
of aquatic environments where it can survive and persist in
association with aquatic plants and animals. Humans acquire
cholera by ingesting V. cholerae contaminated food or water [1].
Upon ingestion, V. cholerae colonizes the small intestine where a
complex regulatory cascade is induced, resulting in the production
of several important virulence factors including cholera toxin (CT)
and the toxin co-regulated pilus (TCP) [2,3]. CT is an AB-type
enterotoxin that is responsible for the secretory diarrhoea that is
characteristic of cholera [4]. The TCP is a type IV bundle forming
pilus that is essential for intestinal colonization of both humans
and laboratory animals [2,5–7]. CT and TCP production are
tightly controlled by a hierarchical regulatory system called the
ToxR regulon [8,9]. In response to unknown stimuli, ToxR and
TcpP, two membrane associated transcriptional regulators,
activate transcription of toxT [3,10–12]. ToxT, an AraC-family
transcriptional regulator, directly activates the expression of the
ctxAB and the tcpA-F operons which encode for the production of
CT and the TCP, plus a number of accessory virulence genes [13–
15].
In order to colonize and survive in the host, V. cholerae must
protect itself from the toxic effects of antimicrobial compounds
that are present in the gastrointestinal tract (GI). V. cholerae does
this by limiting the uptake and intracellular accumulation of toxic
antimicrobial molecules that are present in the GI tract. This is
accomplished by modulating the outer membrane permeability
(e.g. through the production of porin proteins and cell envelope
modifications) in conjunction with efflux of the antimicrobial
molecules via active efflux transporters [16–20]. There are five
different active efflux systems described in bacteria: the ATP-
binding cassette superfamily (ABC), the small multidrug resistance
family (SMR), the multi antimicrobial extrusion protein family
(MATE), the major facilitator superfamily (MFS), and the
resistance-nodulation-cell division superfamily (RND) [21]. The
RND family is particularly interesting because of its broad
substrate specificity and its association with multidrug resistance
in many Gram negative pathogens. Individual RND efflux
systems, including the V. cholerae VexAB-TolC [22], Escherichia coli
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e38208
AcrAB-TolC [23], and Pseudomonas aeruginosa MexAB-OprM
systems [24], have been shown to efflux chemically diverse
antimicrobial compounds including: dyes, detergents, antibiotics,
and antimicrobial peptides [25].
RND efflux systems are tripartite transporters that function as
proton-substrate antiporters [26,27]. RND efflux systems are
composed of an outer membrane pore protein (OMP) that is
homologous to E. coli tolC, a periplasmic membrane fusion protein
(MFP), and an integral cytoplasmic membrane pump protein
belonging to the RND superfamily of transporters [27–31]. These
three components function to form a channel for the extrusion of
substrates from within the cell envelope to the external environ-
ment. Most Gram negative pathogens encode multiple RND
efflux systems; V. cholerae encodes six. In V. cholerae, each RND
system is separately encoded in an operon structure wherein the
RND efflux pump protein has at least one associated MFP whose
gene is located upstream of the pump gene. It appears that all six
RND efflux systems share the same TolC OMP which is encoded
separately on the chromosome [32]. Previous work in our
laboratory showed that three of the RND efflux pumps (VexB,
VexD, and VexK) were required for antimicrobial resistance
in vitro. The VexB RND efflux pump exhibited a very broad
substrate specificity and contributed resistance to bile acids,
detergents, and several antibiotics. In contrast, the VexD and
VexK RND pumps appeared to only efflux bile acids and
detergents, respectively [22,32].
Recently, our laboratory reported that the V. cholerae RND
efflux systems were not only important for antimicrobial resistance
and intestinal colonization, but were also important for CT and
TCP production [32]. A mutant that lacked all six RND efflux
pumps (i.e. DRND) was attenuated for CT and TCP production
and was hypersensitive to antibiotics. Although the VexB, VexD,
and VexK efflux pumps contributed to in vitro antimicrobial
resistance, a mutant lacking the vexBDK genes produced WT levels
of CT and TcpA. This finding suggested that one or more of the
three remaining RND pumps (VexF, VexH, and VexM) must
function in virulence factor production. In this study we have
further characterized these three RND efflux pumps. Using a
genetic approach to generate mutant strains with the RND efflux
pumps deleted in various permutations, we found that the VexH
RND efflux pump contributed to antimicrobial resistance, CT and
TCP production, and successful colonization of the infant mouse
small intestine. VexF and VexM did not appear to function in
antimicrobial resistance in vitro, but were required for high level
production of CT and TCP.
Materials and Methods
Ethics Statement
This study was performed in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. The
animal protocol (#1505R2) was approved by the Institutional
Animal Care and Use Committee of the University of Tennessee
Health Science Center.
Strains and Growth Conditions
Bacterial strains and plasmids used in this study are listed in
Table 1. E. coli strain EC100Dpir+ was used for all cloning
experiments. E. coli strain SM10lpir [33] was used for conjugation
of plasmids into V. cholerae. All V. cholerae strains used in this study
were derivatives of O1 El Tor strain N16961 [34]. V. cholerae
strains N16961 and N16961 DlacZ were used as the wild-type
(WT) control strains in all experiments. All bacterial strains were
grown in Luria-Bertani (LB) broth or on LB agar at 37uC. V.
cholerae was grown in AKI broth under AKI growth conditions for
the CT and TCP bioassays [35]. AKI growth conditions were as
follows: a fresh saturated overnight LB broth culture of the
indicated strain was inoculated 1:10,000 into 10 mL of AKI broth
in a 186175 mm test tube. The test tube was then incubated
statically at 37uC for four hours when the broth culture was
transferred into a sterile 125 mL Erlenmeyer flask. The Erlen-
meyer flask was incubated with shaking overnight before CT and
TCP production was assessed. Bacterial stocks were maintained at
280uC in LB broth containing 25% glycerol. Growth media was
supplemented with carbenicillin (Cb) and streptomycin (Sm) at
100 mg/mL when required.
Chemicals and Enzymes
Enzymes for cloning experiments were purchased from New
England Biolabs (Beverly, MA). Bacterial growth media was
purchased from Difco (Lawrence, KS) and chemicals were
purchased from Sigma-Aldrich (St Louis, MO).
Mutant Construction
Unmarked in-frame deletions of the RND efflux pump protein
gene in each respective strain was constructed by allelic exchange
using genetic constructs and methods that have been previously
described [22,32]. The DvexBDHK, DvexBHK, DvexBDH, and
DvexBH mutants were derived by deletion of vexH in strains JB740,
JB531, JB694, and JB495, respectively. The DvexHK, DvexDK, and
DvexDHK mutants were derived by deletion of vexK deletion in
strains JB116, JB692, and JB186, respectively.
Antimicrobial Susceptibility Assays
Antimicrobial susceptibility tests were performed using antibi-
otic and detergent gradient agar plates as previously described
[32,36]. Each 969 cm gradient plate was inoculated with six
strains, including N16961 and DRND which served as internal
controls, before being incubated at 37uC. The following day the
length of bacterial growth along the antimicrobial gradient was
recorded for each strain. Reported values represent the average
from a minimum of three independent experiments.
CT and TCP Quantification
CT and TCP production were assayed as previously described
[32] from cultures grown under AKI growth conditions. CT was
quantified using a GM1 ganglioside ELISA. TCP production was
quantified by Western immunoblotting using a polyclonal
antibody that was directed towards TcpA, the pilin subunit of
the TCP [32]. The polyclonal antisera against CT and TcpA were
kindly provided by John Mekalanos (Harvard Medical School,
Boston, MA).
Growth Analysis in the Infant Mouse Model
The colonization phenotype of the RND efflux mutants were
assessed using the infant mouse competition assay as previously
described [32,37]. Briefly, 5–7 day old mice were separated from
their mothers 2 h prior to inoculation. The infant mice were then
anaesthetized with isoflurane (Aceto Pharm, NY) and inoculated
by gavage using a 30 cm length of 0.0110 60.0240 polyethylene
tubing that was attached via a 30.5 GA needle to a 1 cc syringe
containing the inoculum. The inoculum consisted of a mixture of
the wild-type strain (lacZ+) and the RND mutant strain (lacZ-) at a
1:1 or 1:100 ratio (WT:mutant) and administered in a 50 mL
volume that contained ,2.56104 cfu of each strain; for the 1:100
inoculum the mutant titer was increased to ,2.56106 cfu. An
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aliquot of the inoculum was also serially diluted and spread onto
LB plates containing Sm and X-gal to verify the input ratio.
Following inoculation the mice were kept in a humidified
incubator at 30uC. The following day, the infected mice were
sacrificed and the small intestine was removed from above the
cecum and homogenized in 5 mL of sterile phosphate buffered
saline. Serial dilutions of the homogenates were then spread onto
LB agar plates containing Sm and X-gal. The agar plates were
then incubated at 37uC overnight when the resulting bacterial
colonies were quantified as WT (lacZ+) or mutant (lacZ-) based on
colony color. A competitive index (CI) was calculated for each
mutant strain as the ratio of the WT to the mutant in the input
inoculum divided by the ratio of the WT to mutant in the output
from the mouse intestinal homogenates. To determine the in vitro
competitive index, an inoculum consisting of a 1:1 ratio of the test
and control strain was inoculated into fresh LB or media and
cultured with shaking overnight at 37uC before being serially
diluted and spread onto LB plates containing Sm and X-gal to
determine the output ratio. Standard bacteria growth assays in
M9-glycerol minimal media were also performed to control for
potential unknown metabolic differences that could affect growth
of the mutants in vivo. A theoretical CI was calculated for mutant
strains that could not be recovered from the mouse challenge
experiments by using an artificial value of 1 recovered cfu for each
strain.
The infant mouse colonization assay was performed identical to
the competition assay with the exception that the inoculum
consisted of a single strain of V. cholerae with the mice receiving
either 26106 or 26108 cfu. Following overnight incubation, the
intestinal homogenates were serially diluted before being spread
onto LB-Sm agar plates to enumerate the bacterial loads in the
small intestine of each mouse.
Results
Function of VexH in Antimicrobial Resistance
Deletion of vexH alone did not affect V. cholerae susceptibility to
any of the tested antimicrobial compounds (Table 2). This is
consistent with the reported functional redundancy among the V.
cholerae RND efflux pumps [32]. Deletion of vexH in a DvexB
background resulted in increased sensitivity to Triton X-100,
ampicillin and novobiocin suggesting that this detergent and these
antibiotics were substrates for the VexH RND efflux pump. This
finding was corroborated by the corresponding increase in
susceptibility to ampicillin and novobiocin in the DvexBDKH strain
Table 1. Bacterial strains, Plasmids, and Oligonucleotides.
Strain Genotype Strain # Source
Vibrio cholerae
N16961-Sm Spontaneous Streptomycin-resistant 01 El Tor strain N16961 DlacZ JB58 [22]
DvexH N16961-Sm DvexH JB116 [32]
DvexDH N16961-Sm DvexD DvexH JB186 [32]
DvexDHM N16961-Sm DvexD DvexH DvexM JB386 [32]
DvexDF N16961-Sm DvexD DvexF JB435 [32]
DvexDFHM N16961-Sm DvexD DvexF DvexH DvexM JB459 [32]
DvexDFHKM N16961-Sm DvexD DvexF DvexH DvexK DvexM JB464 [32]
DRND N16961-Sm DvexB DvexD DvexF DvexH DvexK DvexM JB485 [32]
DvexB N16961-Sm DvexB JB495 [22]
DvexK N16961-Sm DvexK JB528 [32]
DvexBK N16961-Sm DvexB DvexK JB531 [32]
DvexD N16961-Sm DvexD JB692 [22]
DvexBD N16961-Sm DvexB DvexD JB694 [22]
DvexBDHK N16961-Sm DvexB DvexD DvexH DvexK DT12 This study
DvexBHK N16961-Sm DvexB DvexH DvexK DT23 This study
DvexBDH N16961-Sm DvexB DvexD DvexH DT30 This study
DvexBH N16961-Sm DvexB DvexH DT60 This study
DvexHK N16961-Sm DvexH DvexK DT64 This study
DvexDK N16961-Sm DvexD DvexK DT70 This study
DvexDHK N16961-Sm DvexD DvexH DvexK DT76 This study
Escherichia coli
EC100Dpir+ F- mcrA D (mrr-hsdRMS-mcrBC) W80dlacZDM15 DlacX74 recA1 endA1 araD139 D (ara,
leu)7697 galU galK l- rpsL (StrR) nupG pir+
Epicentre
SM10lpir thi-1 thr leu tonA lacY supE recA::RP4-2-4-Tc::Mu Kmr (l pirR6K) [64]
Plasmids
pWM91 Suicide plasmid vector used for allelic exchange [65]
pM132 pWM91:: DVC0914 [32]
pM133 pWM91:: DVC1673 [32]
doi:10.1371/journal.pone.0038208.t001
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relative to the parental DvexBDK strain (Table 2). Novobiocin was
also found to be a substrate for the VexB and VexK RND efflux
systems as evidenced by the increased susceptibility observed for
these mutants.
VexB and VexD were previously shown to efflux bile salts.
Therefore vexH was deleted in the DvexBD background in order to
test if vexH contributed to bile salt resistance. The resulting
DvexBDH mutant exhibited an increase in susceptibility to cholate
and deoxycholate (Table 2). A similar increase in bile salt
susceptibility was observed following the introduction of the vexH
deletion into a DvexBDK background. These results support the
conclusion that bile salts were substrates for the VexH RND efflux
pump. The observation that the cholate and deoxycholate
susceptibility results were identical for the DvexBDHK strain and
the DRND strain supported the conclusion that the VexB, VexD,
VexH, and VexK RND efflux pumps were responsible for V.
cholerae resistance to bile acids in vitro.
The VexF and VexM Pumps do not Function in
Antimicrobial Resistance in vitro
The DvexBDHK mutant had the same antimicrobial susceptibil-
ity profile as the DRND mutant for all of the tested antimicrobial
compounds, including cholate, deoxycholate, Triton X-100, SDS,
erythromycin, Polymyxin B, novobiocin, ampicillin, and penicillin
(Table 2 and data not shown). This suggested that neither VexF
nor VexM functioned in antimicrobial resistance in vitro.
Multiple RND Efflux Pumps Contribute to Virulence
Factor Production
CT production in the V. cholerae DRND mutant was decreased
by ,70% relative to WT (Fig. 1a) with a corresponding decrease
in TCP production (Fig. 1b). This is in agreement with previously
reported work [32] and was used as a RND efflux-negative
reference for analysis of CT and TCP production by the RND
mutant strains generated in this study. CT and TcpA production
in the DvexBH, DvexHK, DvexDK, DvexBDH, DvexBDK, DvexBHK,
DvexDHK, DvexDFHM, and DvexDFHKM mutants (Fig. 1a, 1b, and
data not shown) was not statistically different from WT. In
contrast, CT and TcpA production in the DvexBDHK mutant was
reduced by ,45% relative to WT (Fig. 1a and 1b), suggesting that
these four efflux pumps were required for virulence factor
production. The observation that the presence of a functional
copy of any one of these four RND efflux pumps resulted in a WT
phenotype suggested that there is redundancy among these pumps
for their function in CT and TCP production. The finding that the
DvexBDHK mutant produced more CT and TcpA than the DRND
mutant suggested that VexF and/or VexM also contributed to
virulence factor production and support the conclusion that at
least five of six RND efflux pumps are required for high-level
production of CT and TcpA.
VexH Contributes to in vivo Colonization
The competitive index (CI) is a measure of fitness of a test strain
relative to the WT strain for colonization of the infant mouse small
intestine. Mutants that are able to compete equally with the WT
strain exhibit a CI of ,1, whereas mutants that are outcompeted
by the WT (i.e. attenuated mutants) will have a CI of ,1. Analysis
of the mutants constructed in this study showed that the DvexBH,
DvexHK, DvexDK, DvexDHK and DvexBHK strains competed equally
with the WT strain (Fig. 2a). Similar results were previously
reported for the DvexBD strain [32]. In contrast, the DvexBDH and
DvexBDHK mutants were found to be severely attenuated and
could not be recovered from the infant mice when inoculated at a
1:1 ratio (data not shown). The in vivo attenuation of these
mutants did not emanate from an apparent growth defect as all of
the mutants competed equally with WT during in vitro
Table 2. Antimicrobial susceptibility of V. cholerae RND mutants.
Mean length of mutant growth relative to WT (s.d.)1
Cholate Deoxycholate Triton X-100 Novobiocin Ampicillin
Strain 5% 0.05% 3% 0.01% 0.01% 0.6 mg/mL 10 mg/mL 2 mg/mL
N16961-Sm 100(0) 100(0) 100(0) 100(0) 100(0) 100(0) 100(0) 100(0)
DvexB 100(0) 100(0) 100(0) 100(0) 34.4(63.1){ 66.7(625.5){ 22.9(67.8){ 100(0)
DvexH 100(0) 100(0) 100(0) 100(0) 100(0) 75.7(629.4) 100(0) 100(0)
DvexBD NG 58.9(614.1){ NG 73.9(65.5){ 35.6(61.6){ 58.9(613.5){ 40.0(614.6){ 100(0)
DvexBH 100(0) 100(0) 100(0) 100(0) 24.0(64.3)* 19.3(62.7)* NG 20.6(63.9)*
DvexBK 100(0) 100(0) 100(0) 100(0) 23.9(64.8)* 23.2(610.5)* 22.0(610.2){ 100(0)
DvexBDH NG 31.1(61.6) ¡ NG 47.2(60.1) ¡ 26.4(68.2) 19.3(62.6) NG 20.7(61.7)*
DvexBDK NG 38.9(61.6) ¡ NG 47.2(60.1) ¡ 23.1(64.8) 24.6(69.5) 23.8(610.4){ 100(0)
DvexBHK 100(0) 100(0) 100(0) 100(0) 24.3(64.6) 8.2(68.9) NG 22.0(61.1)*
DvexDHK 34.4(61.6){ 100(0) 100(0) 100(0) 100(0) 62.2(631.8) 100(0) 100(0)
DvexBDHK NG 25.9(63.32) NG 33.3(68.9) 23.6(63.3) 12.8(65.4) NG 19.2(62.3)*
DRND NG 25.9(63.32) NG 34.8(66.8) 23.8(65.9) 10.2(68.8) NG 23(62.9)*
Antimicrobial susceptibility was determined using antibiotic and detergent gradient agar plates.
1The length of the mutant bacterial growth across the 90690 mm gradient plate normalized to 100 mm. Data represents the average of three or more experiments with
the standard deviation in parenthesis. Unpaired t-test was used to determine significance.
{p,0.001 compared to N16961-Sm;
*p,0.05 compared to DvexB;
p,0.05 compared to DvexBD;
¡p,0.05 compared to DvexBDHK. NG: no bacterial growth.
doi:10.1371/journal.pone.0038208.t002
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competitive growth assays and there were no differences in the
growth kinetics of the strains in minimal media (data not shown).
There was a possibility that the detection limit of the infant
mouse colonization assay hindered our ability to recover severely
attenuated mutant strains (e.g. DvexBDH, DvexBDHK, and DRND)
in the intestinal homogenates. To compensate for this the
challenge inoculum was biased for the mutant strains by 100-
fold (i.e. 1:100 ratio of WT to mutant cells) which resulted in an
,2 log increase in the detection the limit. To validate that the
biased input did not affect the CI, we tested the DvexDHK strain
which competed equally with the WT strain at the 1:1 ratio. The
results showed that the DvexDHK competed equally with the WT
strain at the 1:100 input ratio, confirming that the biased input did
not affect the CI value (Fig. 2b). The modified assay was then used
to test the DvexBDH, DvexBDK, DvexBDHK, and DRND strains.
The results of this analysis confirmed the severely attenuated
phenotype of each strain (Fig. 2b). However, the DvexBDH and
DvexBDHK strains, which could not be recovered from infant mice
when inoculated at the 1:1 ratio, were recovered in 30% of the
challenged mice using the modified assay. Using data from the
colonized mice, the DvexBDH and DvexBDHK strains had CI’s that
were reduced by 3.7 and 4.1 log units (Fig. 2B). The DRND strain
still could not be recovered from the mice which is consistent with
this mutant having the greatest colonization defect with a.4.8 log
reduction in its CI.
Despite the modifications to the colonization competition assay,
the ability to quantify colonization differences between highly
attenuated mutants (e.g. the DvexBDH, DvexBDHK, and DRND
strains) was still limited. Therefore, we assessed the ability of these
three highly attenuated strains to colonize the infant mouse small
intestine in the absence of the WT competitor strain (Fig. 3). Mice
were challenged with the mutants at two inoculums: ,106 cfu/
mouse and ,108 cfu/mouse. The 106 cfu/mouse inoculum was
equal to the mutant titer used in the modified competition assay
while the 108 cfu/mouse inoculum was used to determine if
increasing the challenge dose would facilitate colonization by the
mutant strains.
The WT strain and DvexBDK mutant colonized 100% of the
challenged infant mice when administered at 106 cfu/mouse.
However, the DvexBDK mutant exhibited an apparent in vivo
growth defect since the mutant replicated to a final in vivo titer
was ,2 log units lower per mouse than was observed with the WT
Figure 1. CT and TCP production by RND mutants. CT and TCP
production in the indicated strains was determined following growth
under AKI conditions. CT (A) and TcpA (B) were detected by CT GM1-
ELISA and TcpA Western immunoblotting, respectively. Error bars
represent the standard deviation of the mean from three or more
experiments. Statistical analysis was performed by one-way ANOVA.
*p,0.05 compared to wild-type (WT); **p,0.05 compared to all tested
strains.
doi:10.1371/journal.pone.0038208.g001
Figure 2. Infant mouse colonization assays with the RND efflux
mutants. Competition assays were performed using the infant mouse
colonization assay as described in the Materials and Methods. Infant
mice were challenged with a ,105 cfu inoculum containing a mixture
of wild-type and the indicated mutant at a ratio of 1:1 (A) or 1:100 (B).
The competitive index was calculated as the ratio of mutant to wild-
type recovered from the small intestine, corrected for the ratio of
mutant to wild-type that was present in the inoculum. Each symbol
represents one mouse. *The DRND mutant was not recovered from
mice necessitating the calculation of a theoretical CI as described in the
Materials and Methods. Mean and standard deviation are indicated by
horizontal bars. Significance was determined using the Mann-Whitney
U t-test. (1) p,0.01.
doi:10.1371/journal.pone.0038208.g002
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(Fig. 3a). Inoculation of mice with 106 cfu of the DvexBDH mutant
resulted in colonization of about 50% of the challenged mice. In
the successfully colonized mice, the DvexBDH titers were at least 5-
logs lower than was observed in mice challenged with the WT
strain and 3-logs lower than the output observed in mice
challenged with the DvexBDK mutant (Fig 3a). This indicates that
the in vivo growth defect of the DvexBDH mutant was significantly
greater than what was observed for the DvexBDK mutant. This is
also consistent with the severe attenuation of this mutant in the
colonization competition assays. When the challenge inoculum
was increased to 108 cfu/mouse the DvexBDH mutant successfully
colonized 100% of the challenged mice. In addition, the bacterial
titer in each mouse also increased by 3-logs to a level that was
equivalent to what was observed with the DvexBDK mutant
(Fig. 3b). The increase in the output titer was limited to the
DvexBDH mutant and was not observed when mice were
challenged with 108 cfu of the DvexBDK mutant. The DvexBDHK
and DRND mutants did not successfully colonize the intestinal
tract at either inoculum level (Fig. 3a and 3b). This indicates that if
either of these strains is able to colonize the infant mouse small
intestine, the mutants were present at very low levels that were
below our limits of detection. Since we were unable to distinguish
an in vivo difference between these two strains, other approaches
will be required to assess the function of VexF and VexM in vivo.
Discussion
Deletion of vexH in the WT background did not result in an
observable phenotype. There were two plausible explanations for
this lack of phenotype: either VexH did not contribute to
antimicrobial resistance, or its contribution was masked due to
redundancy with one or more of the other five V. cholerae RND
efflux pumps. The latter was proven true since the introduction of
the vexH deletion into V. cholerae lacking the vexBDK RND efflux
pumps resulted in increased susceptibility to a number of
antimicrobial compounds (Table 2). This showed that VexH
possessed a relatively broad substrate specificity that was second
only to VexB (Table 2 and data not shown). VexH contributed to
cholate, deoxycholate, Triton X-100, novobiocin, and ampicillin
resistance, but not to penicillin or erythromycin resistance (which
were VexB substrates). Redundant substrate specificity between
VexH and VexB is consistent with the observation that VexH has
the largest amino acid sequence identity in common with VexB
among the V. cholerae RND efflux pumps [32]. The V. cholerae
DvexBDHK mutant exhibited the same antimicrobial susceptibility
profile as the DRND strain (Table 2). This suggests that VexB,
VexD, VexK, and VexH are the only RND efflux pumps that
contribute to antimicrobial resistance in vitro. Although these four
RND efflux pumps were redundant for some substrates, they do
not have equal activity. All four pumps contributed to bile acid
resistance, yet the presence of VexB or VexD is sufficient to
provide a WT level of resistance in the absence of VexH and/or
VexK (Table 2) [22]. Only in a DvexBD mutant background can
the contribution of VexH and VexK be observed. Together this
suggests that VexB and VexD are major contributors to bile acid
resistance in vitro, while VexH and VexK have minor roles. This
conclusion is likely only relevant to V. cholerae grown under the
conditions used in our assays as there are reports to suggest that
the expression of the RND efflux systems are responsive to
environmental cues including those present in vivo in rabbit ileal
loops and in humans [22,38–40].
The antimicrobial susceptibility results also suggested that
neither VexF nor VexM contributed to antimicrobial resistance
in vitro. This was a surprising finding as vexF from a non-O1 Vibro
was reported to produce a functional efflux system when expressed
in E. coli in conjunction with V. cholerae tolC [41]. This discrepancy
may reflect strain or functional differences of VexF in a
Figure 3. Colonization of the infant mouse small intestine by V. cholerae RND efflux mutants. Infant mice were challenged with ,66106
cfu (A) or ,86107 cfu (B) of the indicated V. cholerae mutant. Bacterial loads in the small intestine were assessed after overnight incubation. Means
and standard deviation are indicated by horizontal bars. The Mann Whitney U t-test was used to determine significance. (1) p,0.05 compared to all
tested strains; (2) p,0.05 compared to DvexBDK; (3) p,0.05 compared to the ,66106 cfu (A) DvexBDH challenge.
doi:10.1371/journal.pone.0038208.g003
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heterologous system [41]. Alternatively, it is also possible that
VexF or VexM are expressed under conditions or efflux substrates
other than tested in this study (see below).
The finding that V. cholerae produces redundant RND efflux
pumps that function in bile acid and detergent resistance seems to
be an important adaption to facilitate colonization of the small
intestine. Redundant bile efflux pumps would provide an obvious
benefit since intestinal bile is a natural host defence that
microorganisms must overcome in order to colonize the small
intestine [1]. Consistent with bile salts being a major substrate of
the RND efflux pumps, a number of studies have suggested that
bile salts and other components of bile function to induce the
expression of the RND efflux systems. In 2004, Chatterjee et. al.
[42] reported that V. cholerae grown in bile accumulated lower
amounts of hydrophobic compounds than V. cholerae grown
without bile, a phenotype they attributed to bile-dependent
induction of active efflux. More recently, we and others have
shown that transcription of the vexAB and vexCD RND efflux
systems are upregulated in the presence of bile acids [32,40].
These results are consistent with the hypothesis that substrates of
the individual RND efflux pumps function as effectors to
upregulate the expression of the respective RND efflux system.
While the chemical effectors that control the expression of vexH are
unknown, a recent study has suggested that vexH expression may
be responsive to the iron status of the cell [43–45]. This finding,
combined with the hypothesized iron limiting conditions V. cholerae
may encounter late during infection [46], could explain the in vivo
induction of VexH in humans during infection [38]. If vexH
transcription is up-regulated during in vivo colonization as a
response to iron availability, then VexH could have a greater role
in vivo than indicated by our in vitro analysis.
The function of theRND efflux systems inmediating resistance to
host defences is correlated with the ability of many bacterial
pathogens to survive, invade, and colonize their hosts [47–50]. We
therefore expected that V. cholerae RND efflux mutants with similar
antimicrobial susceptibility profiles would behave similarly in vivo,
butour results revealed this tobe false.Forexample, theDvexBDKand
DvexBDHmutants exhibited similar susceptibilityprofiles forbile salts
anddetergents, but theDvexBDHmutantwasmoreattenuated invivo
thantheDvexBDKmutantandlessattenuatedthantheDvexBDHKand
DRNDmutants.Consistentwith this theDvexBDHmutant requireda
two-log higher inoculum than did theDvexBDKmutant to efficiently
colonize the small intestine (108 vs. 106 cfu/mouse, respectively;
Fig. 3). This is in contrast toWTwhich can efficiently colonize when
administered at inoculums of 103–104 cfu/mouse [51]. Even at the
higher inoculums, neither mutant was able to reach titers in the
intestine equivalent toWT. It was noteworthy that administration of
the DvexBDH mutant at 108 cfu/mouse resulted in a three-log
increase in the bacterial outputs from the colonized mice relative to
inoculation at 106 cfu/mouse. This phenomenon was not observed
with theDvexBDKmutant (Fig. 3b). Together this suggests that the in
vivo roles of theRNDefflux systems donot completely correlatewith
their contributions to in vitro antimicrobial susceptibility WT V.
cholerae.The fact that theDvexBDHmutantcangrowtosimilar titersas
theDvexBDKmutant when given at a high inoculum suggests that the
DvexBDH mutant may be defective in colonization of the intestinal
epithelium.
The intestinal epithelium is covered by a thick mucus layer which
providesadiffusionbarrieragainstantimicrobial compounds thatare
present in the lumen (e.g. bile) [52].One implication of this is that the
epithelial surface likely represents amore amenable environment for
growth of antimicrobial hyper-susceptible organisms like the
DvexBDK and DvexBDH efflux mutants. Thus one possible explana-
tion for the colonization difference observed between the DvexBDK
andDvexBDHmutants is that they exhibit differential susceptibility to
antimicrobial compounds that are present in the intestinal lumen.
This idea is supported by the observation that VexH has a broader
substraterange thanVexK(Table2)whichwouldmakeVexHamore
important during colonization than VexK. The finding that both
VexHandVexKwere inducedduring colonizationof thehumangut
[38] corroborates the idea that these two RND efflux pumps are
induced in vivo. Alternatively, it is possible that the colonization
differences are due to unknown in vivo growth defects or differential
effects on the in vivo induction of the ToxR regulon (see below).
The CT and TCP bioassays showed that VexB, VexD, VexH,
and VexK contributed to virulence factor production. However,
the DvexBDH, DvexBDK, DvexBHK, and DvexDHK mutants were not
different from WT for CT and TCP production (Fig.1). This
suggests that these four efflux systems were functionally redundant
for CT and TCP production. Consistent with this result was the
finding that VexB was able to complement for the loss of the five
other RND efflux systems [32] which was evidenced by the
observation that a vexDFHKM mutant (which is vexB+) was
phenotypically identical to WT (Fig. 2). The function of VexF
and/or VexM in CT and TCP production was evident as the
mutant that lacked vexBDHK was attenuated for CT and TCP
production, while the mutant that lacked all six RND efflux
systems (i.e. DRND) produced even less CT and TCP. This
observation provides the evidence that VexF and/or VexM are
required for WT CT and TCP production. This also indicates that
neither VexF nor VexM are able to fully compensate for the loss of
the other four RND efflux systems.
Although much is known about how RND efflux systems
contribute to antimicrobial resistance, the mechanism of how they
affect virulence factor production is not known. We previously
showedthat theV.choleraeRNDeffluxsystemseffectonvirulencegene
expression mapped to tcpPH transcription [32], but the connection
betweenRNDefflux systemsand tcpPH transcriptionhasnotyetbeen
determined.Wehypothesize that theRNDefflux systems function to
modulate the intra- or extracellular concentration of a lowmolecular
weight molecule that functions as a negative effector of tcpPH
transcription. Efflux-dependent modulation of an effector molecule
represents a mechanism that could be used to link efflux to gene
expression. This process could be used to fine-tune the expression of
virulence genes in response to the growth environment. For example
theeffluxofanygiveneffectormolecule,whichwouldaffect itscellular
distribution, would be dependent upon the presence of competing
efflux substrates in the bacterium’s growth environment (e.g.
components of bile in the GI tract). Consistent with this hypothesis,
anumberofpotential lowmolecularweight effectorcompoundshave
beendescribed in the literature thataffectvirulence factorproduction
including: fatty acids, bile acids, quorum sensing molecules, cyclic
nucleotides, and cyclic peptides [53–58]. Significantly, all of these
compounds have been reported to be effluxed in Gram negative
bacteria [42,59,60] which suggests the possibility that effector efflux
could be applicable to other bacterial pathogens where the RND
efflux systems have also been reported to influence virulence factor
production [47,61]. In addition to negatively affecting tcpPH
transcription, efflux could also impact genes downstream of tcpPH
in the ToxR regulon. For example, given the role of the RND efflux
systems in bile resistance, it is possible that the loss of efflux could
impact intracellular fattyacidspoolsandthusaffectToxTactivityand
virulence factor production [62,63].
In summary, we have shown that VexH contributes to
antimicrobial resistance and exhibits broad substrate specificity.
VexH was found to be important for intestinal colonization and
virulence factor production; phenotypes consistent with vexH being
in vivo induced in humans [38]. We have also shown that the V.
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cholerae RND efflux pumps have redundant functions, not only in
antimicrobial resistance, but also in virulence factor production.
Collectively these results support the conclusion that the RND
efflux system contribute to V. cholerae pathogenesis in two ways.
First, the RND efflux systems function to provide the bacterium
with protection against antimicrobial compounds that are present
in the host. Second, the RND efflux systems are required for
efficient production of virulence factors.
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